Jones Financial Companies Lllp acquired a new stake in Chemed Corporation (NYSE:CHE - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,114 shares of the company's stock, valued at approximately $2,531,000.
Other institutional investors have also recently made changes to their positions in the company. Kayne Anderson Rudnick Investment Management LLC grew its holdings in shares of Chemed by 2.6% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 597,175 shares of the company's stock valued at $367,454,000 after purchasing an additional 15,041 shares in the last quarter. Neuberger Berman Group LLC boosted its position in Chemed by 3.9% in the 1st quarter. Neuberger Berman Group LLC now owns 521,212 shares of the company's stock valued at $320,712,000 after buying an additional 19,650 shares during the period. Boston Trust Walden Corp grew its stake in shares of Chemed by 1.7% in the first quarter. Boston Trust Walden Corp now owns 246,351 shares of the company's stock worth $151,585,000 after acquiring an additional 4,179 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Chemed by 9.7% in the first quarter. Dimensional Fund Advisors LP now owns 218,675 shares of the company's stock worth $134,547,000 after acquiring an additional 19,421 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Chemed by 3.4% during the first quarter. Northern Trust Corp now owns 215,523 shares of the company's stock worth $132,616,000 after acquiring an additional 6,988 shares during the period. Institutional investors and hedge funds own 95.85% of the company's stock.
Chemed Price Performance
Chemed stock opened at $451.21 on Thursday. The stock has a market cap of $6.57 billion, a PE ratio of 23.20, a P/E/G ratio of 2.55 and a beta of 0.46. The stock's fifty day moving average is $452.65 and its two-hundred day moving average is $532.39. Chemed Corporation has a 1-year low of $408.42 and a 1-year high of $623.60.
Chemed (NYSE:CHE - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.02 by ($1.75). Chemed had a return on equity of 25.83% and a net margin of 11.56%.The business had revenue of $618.80 million for the quarter, compared to analyst estimates of $650.60 million. During the same period in the prior year, the company posted $5.47 earnings per share. The company's revenue was up 3.8% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, research analysts expect that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.
Chemed Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 11th were paid a $0.60 dividend. This is an increase from Chemed's previous quarterly dividend of $0.50. This represents a $2.40 annualized dividend and a yield of 0.5%. The ex-dividend date was Monday, August 11th. Chemed's payout ratio is currently 12.34%.
Insiders Place Their Bets
In other Chemed news, EVP Nicholas Michael Westfall sold 10,012 shares of the firm's stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $421.91, for a total transaction of $4,224,162.92. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Patrick P. Grace sold 150 shares of the business's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the sale, the director owned 3,397 shares of the company's stock, valued at $1,574,135.83. This represents a 4.23% decrease in their position. The disclosure for this sale can be found here. 3.29% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
CHE has been the subject of a number of recent research reports. Jefferies Financial Group upgraded Chemed from a "hold" rating to a "buy" rating and lifted their target price for the company from $490.00 to $550.00 in a report on Tuesday, September 2nd. Royal Bank Of Canada cut their price target on Chemed from $640.00 to $589.00 and set an "outperform" rating on the stock in a report on Thursday, July 31st. Oppenheimer decreased their price objective on Chemed from $650.00 to $580.00 and set an "outperform" rating for the company in a research note on Thursday, July 31st. Bank of America lowered their price objective on Chemed from $610.00 to $595.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Wall Street Zen cut shares of Chemed from a "buy" rating to a "hold" rating in a report on Saturday, July 5th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Chemed presently has a consensus rating of "Buy" and an average target price of $578.50.
Read Our Latest Research Report on Chemed
Chemed Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.